These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Anti-HLA Class I alloantibodies in platelet transfusion refractoriness: From mechanisms and determinants to therapeutic prospects. Couvidou A; Rojas-Jiménez G; Dupuis A; Maître B Front Immunol; 2023; 14():1125367. PubMed ID: 36845153 [TBL] [Abstract][Full Text] [Related]
30. Platelet transfusion therapy for alloimmunized patients: selective mismatching for HLA B12, an antigen with variable expression on platelets. Schiffer CA; O'Connell B; Lee EJ Blood; 1989 Aug; 74(3):1172-6. PubMed ID: 2752158 [TBL] [Abstract][Full Text] [Related]
31. Adverse effect of donor-specific anti-human leukocyte antigen (HLA) antibodies directed at HLA-DP/-DQ on engraftment in cord blood transplantation. Jo T; Arai Y; Hatanaka K; Ishii H; Ono A; Matsuyama N; Mori J; Koh Y; Azuma F; Kimura T Cytotherapy; 2023 Apr; 25(4):407-414. PubMed ID: 36335019 [TBL] [Abstract][Full Text] [Related]
32. ABO compatibility can influence the results of platelet transfusion. Results of a randomized trial. Lee EJ; Schiffer CA Transfusion; 1989 Jun; 29(5):384-9. PubMed ID: 2660333 [TBL] [Abstract][Full Text] [Related]
33. Posttransfusion platelet count increments after ABO-compatible versus ABO-incompatible platelet transfusions in noncancer patients: an observational study. Pavenski K; Warkentin TE; Shen H; Liu Y; Heddle NM Transfusion; 2010 Jul; 50(7):1552-60. PubMed ID: 20210928 [TBL] [Abstract][Full Text] [Related]
34. [Platelet allo-antibodies identification strategies for preventing and managing platelet refractoriness]. Basire A; Picard C Transfus Clin Biol; 2014 Nov; 21(4-5):193-206. PubMed ID: 25277423 [TBL] [Abstract][Full Text] [Related]
35. Platelet transfusion refractoriness in highly immunized beta thalassemia children undergoing stem cell transplantation. Marktel S; Napolitano S; Zino E; Cappelli B; Chiesa R; Poli F; Crocchiolo R; Ronchi P; Rossini S; Ciceri F; Roncarolo MG; Fleischhauer K Pediatr Transplant; 2010 May; 14(3):393-401. PubMed ID: 20070557 [TBL] [Abstract][Full Text] [Related]
36. Correlation of platelet crossmatch results by Solid Phase Red Cell Adherence Assay (SPRCA) with post-transfusion platelet count increment in adult hemato-oncology patients of a tertiary care oncology centre in India. Desai P; Sontakke P; Rajadhyaksha S; Navkudkar A Transfus Apher Sci; 2020 Oct; 59(5):102842. PubMed ID: 32586771 [TBL] [Abstract][Full Text] [Related]
37. A pilot trial of complement inhibition using eculizumab to overcome platelet transfusion refractoriness in human leukocyte antigen allo-immunized patients. Vo P; Purev E; West KA; McDuffee E; Worthy T; Cook L; Hawks G; Wells B; Shalabi R; Flegel WA; Adams SD; Reger R; Aue G; Tian X; Childs R Br J Haematol; 2020 May; 189(3):551-558. PubMed ID: 32086819 [TBL] [Abstract][Full Text] [Related]
39. Platelet transfusion refractoriness responding preferentially to single donor aphaeresis platelets compatible for both ABO and HLA. McVey M; Cserti-Gazdewich CM Transfus Med; 2010 Oct; 20(5):346-53. PubMed ID: 20492602 [TBL] [Abstract][Full Text] [Related]
40. Dilution is not the solution: acute hemolytic transfusion reaction after ABO-incompatible pooled platelet transfusion. Guarente J; Harach M; Gould J; Karp JK; Peedin AR Immunohematology; 2019 Sep; 35(3):91-94. PubMed ID: 31621366 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]